This new sponsored research will focus on the development of a new novel class of compounds that inhibit glycolysis, the metabolic pathway essential to the survival of many human tumors.
The company will have a right to an exclusive license to any new patents derived from this research as the company expands its support of Dr Priebe’s drug discovery and development efforts.
This sponsored research will initially focus on evaluation of the selected lead compounds with the goal of identifying a superior inhibitor of glycolysis that potently blocks tumor growth.
Dr Priebe is a scientist who has several drugs in clinical development based on research from his laboratory and works at The University of Texas MD Anderson Cancer Center (UTMDACC).
Donald Picker, COO of Oncolin, said: “This agreement expands our commitment to this area of cancer research and our goal of bringing the best drug in this therapeutic class into clinical development for patients.”